MIRA
INFORM REPORT
|
Report Date : |
07.6.2008 |
IDENTIFICATION
DETAILS
|
Name : |
UNISIS CORP |
|
|
|
|
Registered Office : |
Sankieemu Bldg 5F, 5-14-3 Nishinippori Arakawaku Tokyo 116-0013 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.07.2007 |
|
|
|
|
Date of Incorporation : |
September 1978 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturer of Anesthetic Syringe Needles |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Maximum Credit Limit : |
YEN 64.3 Million |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Regular |
name & address
UNISIS CORP
REGD NAME: KK Unisis
MAIN OFFICE: Sankieemu Bldg 5F,
5-14-3 Nishinippori Arakawaku Tokyo 116-0013 JAPAN
Tel:
03-3802-6580 Fax: 03-3802-6851
E-Mail address: info@unisis.co.jp
ACTIVITIES
Mfg of anesthetic syringe needles
BRANCHES
Nil
FACTORY(IES)
Saitama
OFFICER(S)
TOMOE OKUDAIRA, PRES
Masatoshi Oda, s/mgn dir
Yoko Ishikawa, dir
Hidenari Saitoh, dir
Yen Amount
In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 1,800 M
PAYMENTS REGULAR CAPITAL Yen 23 M
TREND STEADY WORTH Yen 806 M
STARTED 1978 EMPLOYES 65
COMMENT
MFR OF MEDICAL INSTRUMENTS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY
BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT
YEN 64.3 MILLION, 30 DAYS NORMAL TERMS
HIGHLIGHTS
The subject company was established by Hidenari Saitoh, major shareholder & director of the firm, in order to make the most of his experience in the medical business. Tomoe Okudaira took the pres office in Oct 2000. Specializes in mfg anesthetic syringe needles for sub-arachnoids hemorrhage surgery. Goods are exported to about 40 countries in Europe, USA, Mid/South America, S/E Asia, Mid East, other.
FINANCIAL INFORMATION
The sales volume for Jul/2007 fiscal term amounted to Yen 1,800 million, a 2% down from Yen 1,840 million in the previous term. This is referred to production line & inventory adjustments at some of its overseas clients. The recurring profit was posted at Yen 237 million and the net profit at Yen 132 million, respectively, compared with Yen 97 million net profit a year ago. Financials for the previous term were only partially disclosed.
For the current term ending Jul 2008 the net profit is projected at Yen 95 million, on a 3% rise in turnover, to Yen 1,850 million. Business is seen steadily rising.
The financial situation is considered FAIR to GOOD and responsible for ORDINARY business engagements. Max credit limit is estimated at Yen 64.3 million, on 30 days normal terms.
REGISTRATION
Date Registered: Sept 1978
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 160,000 shares
Issued: 46,800 shares
Sum: Yen 23.4 million
Major shareholders (%)
Hidenari Saitoh (51), Tomoe Okudaira (37), Masatoshi Oda (7),
Yoko Ishikawa (5)
No. of shareholders: 4
Nothing detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Manufactures and exports anesthetic syringe needles & other supplies for sub-arachnoids hemorrhage, others (--100%).
Anesthetic syringe needles include: nerve block needles, peridural needles, other.
Clients
[Medical instruments mfrs, wholesalers] Exports to N America (30%), Europe (30%), Mid/South America (20%), other to S/E Asia, Australia, S Africa, Mid East, etc (40 countries worldwide)
No. of accounts
Unavailable
Domestic areas of activities
Nationwide
Suppliers
[Mfrs, wholesalers] Saito Medical Ind, Arakawa Plastics Ind, Shikoku Brush Ind, Sun Giken, Teshima Kogyo, other.
Payment record
Regular
Location
Business area in Tokyo. Office premises at the caption address are leased and maintained satisfactorily.
Bank References
SMBC (Hakusan)
Mizuho Bank (Dozaka)
Relations: Satisfactory
FINANCES: (In Million Yen)
|
Terms Ending: |
31/07/2008 |
31/07/2007 |
31/07/2006 |
31/07/2005 |
|
|
Annual
Sales |
|
1,850 |
1,800 |
1,840 |
1,793 |
|
Recur.
Profit |
|
|
237 |
|
196 |
|
Net
Profit |
|
95 |
132 |
97 |
94 |
|
Total
Assets |
|
|
1,413 |
|
1,563 |
|
Current
Assets |
|
|
840 |
|
905 |
|
Current
Liabs |
|
|
353 |
|
571 |
|
Net
Worth |
(*) |
|
806 |
706 |
614 |
|
Capital,
Paid-Up |
|
|
23 |
23 |
23 |
|
Div.P.Share(¥) |
|
|
100.00 |
100.00 |
100.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
2.78 |
-2.17 |
2.62 |
.. |
|
|
Current Ratio |
|
.. |
237.96 |
.. |
158.49 |
|
N.Worth Ratio |
.. |
57.04 |
.. |
39.28 |
|
|
R.Profit/Sales |
|
.. |
13.17 |
.. |
10.93 |
|
N.Profit/Sales |
5.14 |
7.33 |
5.27 |
5.24 |
|
|
Return On Equity |
.. |
16.38 |
13.74 |
15.31 |
|
Notes: (*) Net Worth for the 31/07/2006 term was estimated
only as financials were only partially
disclosed for the term.
Forecast (or estimated) figures for the 31/07/2008 fiscal
term.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)